CD8A and neoplasm: The fabricated nanoformulation could reprogram the tumor immunosuppressive microenvironment and activate the immune response via increasing the number of M1-phenotype macrophages (by increasing ROS levels by near infrared II (NIR II) irradiation) and anti-tumor CD8+ T cells at the tumor site along with reducing PD-L1 expression and Treg cells infiltration [207].